Sağlıklı Çocuklarla, Dil ve Konuşma Bozukluğu Olan Çocuklar Arasında Vitamin D Düzeyinin Karşılaştırılması

Year 2020, , 158 - 163, 18.03.2020

Saime Sağıroğlu

https://doi.org/10.12956/tchd.562170

Abstract

ÖZ

Amaç: Bu çalışmada, dil ve konuşma bozukluğu olan çocuklar ile vitamin D (25(OH)D3) düzeyi arasındaki ilişki araştırıldı.

Gereç ve Yöntemler: Toplam 200 çocuk çalışmaya alındı. Hasta olarak alınan 124 çocukta; kekemelik (n=62), fonksiyonel

dil gelişim bozukluğu (n=40) ve artikülasyon bozukluğu (n=22) vardı. Kontrol grubuna 76 sağlıklı çocuk alındı.

Hastalarda ve sağlıklı çocuklarda plazmada vitamin D seviyesine bakıldı.

Bulgular: Vitamin D seviyesi; kekemeliği olanlarda 23.36±10.01, fonksiyonel dil gelişim bozukluğu olanlarda 17.82±8.28,

artikülasyon bozukluğu olanlarda 23.68±10.95, kontrol grubunda 26.01±7.4 olarak saptandı. Artikülasyon ve kekemelik

ile kontrol grubu arasında vitamin D açısından anlamlı fark bulunmadı. Fonksiyonel dil gelişim bozukluğu olan çocuklarda,

sağlıklı gruba göre vitamin D değeri daha düşüktü ve istatistiksel olarak anlamlı bir fark saptandı (p<0.001). Ayrıca,

kekemelik şiddeti artıkça vitamin D seviyesinin düşük olduğu saptandı.

Sonuç: Bu çalışmanın sonuçlarına göre, vitamin D düzeyi ile fonksiyonel dil gelişim bozukluğu arasında önemli bir bağlantı

olduğu düşünülebilir. Ancak, yine de, dil ve konuşma bozukluğu olan çocuklarda bu bulguları doğrulamak için daha

fazla çalışmaya ihtiyaç olduğu kanaatindeyiz.

Keywords

Artikülasyon bozukluğu, Fonksiyonel dil bozukluğu, Kekemelik

A Comparison of Vitamin D Levels in Chidren with Language and Speech Disorders and Healthy Children in the Turkish Population

Abstract

ABSTRACT

Objective: This study aimed to investigate the relationship between vitamin D [25(OH)] values with the language and

speech disorders in children.

Material and Methods: A total of 200 children were included in the study, comprising 124 children, with stuttering

(n=62), functional language disorder (n=40) and articulation disorder (n=22) as the patient group and a control group

of 76 healthy children. Vitamin D levels were examined in blood samples taken from both the patient group and the

control group.

Results: Serum vitamin D levels were determined as 23.68 ± 10.95 in patients with articulation disorder, 17.82 ± 8.28

in patients with functional language disorder, 23.36 ± 10.01 in patients with stuttering, and 26.01 ± 7.4 in the control

group. Serum vitamin D values were found to be statistically significantly (p<0.001) lower in children with functional

language disorder than in the healthy control group. It was observed that vitamin D decreased as the severity of the

stutter increased.

Conclusion: According to the results of this study, there can be considered to be an important connection between

vitamin D level and functional language disorder. Nevertheless, further studies are needed to confirm these findings in

children with language and speech disorders.

Keywords

Articulation disorder, Functional language disorder, Stuttering

References

• 1. Silverman FH.Stuttering and Other Fluency Disorders. Illinois: Waveland Press. 2004
• 2. Maria-Mengel MR, Martins Linhares MB. Risk factors for infant developmental problems. Rev Lat Am Enfermagem 2007;15:837– 42.
• 3. Samra HA, Mcgrath JM, Wehbe M. An integrated review of developmental outcomes and late-preterm birth. J Obstet Gynecol Neonatal Nurs 2011;40:399–411.
• 4. Hall NE. Developmental Language Disorder. Semin Pediatr Neurol 1997;4:77-85.
• 5. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008;87:1080-6.
• 6. Holick MF. Vitamin D: importance in the prevention of cancers, type I diabetes, heart disease and osteoporosis. Am J Clin Nutr 2004;79:362-71.
• 7. Lemire JM, Archer DC. 1.25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
• 8. Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DE, Atkinson SA, Josse RG, Feldman S, Kline GA, Rosen C. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010;182:610-8.
• 9. Kiraly SJ, Kiraly MA, Hawe RD, Makhani N. Vitamin D as a Neuroactive Substance:Review. Scientific World Journal 2006;26;125-139.
• 10. Sutherland MK, Wong L, Somerville MJ, Yoong LK, Bergeron C, Parmentier M, et al. Reduction of calbindin-24k mRNA levels in Alzheimer as compared to Huntington hippocampus. Brain Res Mol Brain Res 1993;18:32-42.
• 11. Schoenrock SA, Tarantino LM. Developmental vitamin D deficiency and schizophrenia: the role of animal models. Genes Brain Behav 2016;15:45-61.
• 12. McGrath J, Eyles D, Mowry B, Yolken R, Buka S. Low maternal vitamin D as a risk factor for schizophrenia:a pilot study using banked sera. Schizophr Res 2003;63:73-8.
• 13. Przybelski RJ, Binkley NC. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem Biophys 2007;460:202-5.
• 14. American Psychiatric Association. Diagnostic criteria from DSM-IVTR. Washington DC: American Psychiatric Association 2000;370- 381.
• 15. Luu TM, Vohr BR, Schneider KC, Katz KH, Tucker R, Allan WC, et al. Trajectories of receptive language development from 3 to 12 years pf age for very preterm children. Pediatrics 2009;124;333- 41.
• 16. Martson L, Peacock JL, Calvert SA, Greenough A, Marlow N. Factors affecting vocabulary acquisition at age 2 in children born between 23 and 28 weeks’ gestation. Dev Med Child Neurol 2007;49:591–6.
• 17. Mossabeb R, Wake KC, Finnegan K, Sivieri E, Abbasi S. Language development survey provides a useful screening tool for language delay in preterm infants. Clin Pediatr (Phila) 2012;51:638-44.
• 18. Ouma S, Suenaga M, Bölükbaşı Hatip FF, Hatip-Al-Khatib I, Tsuboi Y, Matsunaga Y. Serum vitamin D in patients with mild cognitive impairment and Alzheimer’s disease. Brain Behav 2018;8:e00936.
• 19. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100-5.
• 20. Brown J, Bianco JI, McGrath JJ, Eyles DW. 1.25-Dihydroxyvitamin D3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 2003;343:139-43.
• 21. Munger KL, Zhang SM, O’Reilly E, Hernan MA, Olek MJ, Willett WC, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62;60-5.
• 22. Mackay-Sim A, Feron F, Eyles D, Burne T, McGrath J. 2004. Schizophrenia, vitamin D, and brain development. Int Rev Neurobiol 59:351-80.
• 23. Wang T, Shan L, Du L, Feng J, Xu Z, Staal WG, Jia F. Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2016;25:453-4.
• 24. Brookes GB. Vitamin D deficiency and deafness: 1984 update. Am J Otology 1985;6:102–7.
• 25. Lemire J. 1,25-Dihydroxyvitamin D3-a hormone with immunomodulatory properties. Z Rheumatol 2000;59:24-7.
• 26. Garcion E, Thanh XD, Bled F, Teissier E, Dehouck MP, Rigault F, Bet al. 1.25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett 1996;216;183-6.
• 27. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100-5.
• 28. Ludlow CL, Loucks T. Stuttering: a dynamic motor control disorder. J Fluen Disord 2003;28:273-95.
• 29. Pool KD, Devous MD, Freeman FJ, Watson BC, Finitzo T. Regional cerebral blood flow in developmental stutterers. Arch Neurol 1991;48:509-12.
• 30. Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord 2013;38:66-87.
• 31. Lawrence M, Barclay DM. Stuttering: A brief review. Am Fam Physician 1998;57:2175-8.
• 32. Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering, Neuroreport 1997;8:767-70.
• 33. Steidl L, Pesak J, Chytilova H. Stuttering and tetanic syndrome. Folia Phoniatr (Basel) 1991;43:7-12.
• 34. Alm PA. Copper in developmental stuttering. Folia Phoniatr Logop 2005;57:216-22.
• 35. Rutter MJ, Bishop D, Pine D, Scott S, Stevenson JS, Taylor EA, Thapar A. Rutter’s child and adolescent psychiatry. 5th. Hoboken (NJ): Wiley-Blackwell 2010
• 36. Harrison LJ, McLeod S. Risk and protective factors associated with speech and language impairment in a nationally representative sample of 4- to 5-year-old children. J Speech Lang Hear Res 2010;53:508-29.
• 37. Yasin A, Aksu H, Ozgür E, Ozgür BG. Speech and language delay in childhood: a retrospective chart review. ENT Updates 2017;7;22-7.